{"id":334,"date":"2026-09-23T06:13:08","date_gmt":"2026-09-23T06:13:08","guid":{"rendered":"https:\/\/noimfine.com\/sph06\/?p=334"},"modified":"2026-09-23T06:13:08","modified_gmt":"2026-09-23T06:13:08","slug":"tecentriq-and-tecentriq-hybreza-fda-approves-first-ctdna-guided-adjuvant-immunotherapies-to-target-residual-muscle-invasive-bladder-cancer-after-surgery","status":"publish","type":"post","link":"https:\/\/noimfine.com\/sph06\/2026\/09\/23\/tecentriq-and-tecentriq-hybreza-fda-approves-first-ctdna-guided-adjuvant-immunotherapies-to-target-residual-muscle-invasive-bladder-cancer-after-surgery\/","title":{"rendered":"Tecentriq and Tecentriq Hybreza: FDA Approves First ctDNA\u2011Guided Adjuvant Immunotherapies to Target Residual Muscle\u2011Invasive Bladder Cancer After Surgery"},"content":{"rendered":"
<\/p>\n
\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n<\/div>\n
\n
\n
Tecentriq<\/a> (atezolizumab) and\u00a0Tecentriq Hybreza<\/a> (atezolizumab and hyaluronidase-tqjs) are prescription immunotherapy medicines used to help the body’s immune system fight cancer. The FDA has now approved them to treat muscle-invasive bladder cancer (MIBC) in adults after surgery (cystectomy) when circulating tumor DNA (ctDNA) is detected, indicating molecular residual disease (MRD), on an FDA-authorized blood test.<\/p>\n

The FDA has also cleared Signatera CDx, a test used to detect ctDNA and help identify patients who may benefit from treatment with these medicines.<\/p>\n

MIBC is an aggressive cancer, with more than 150,000 people worldwide getting bladder removal surgery to treat it, yet it recurs in nearly half of them.<\/p>\n

Tecentriq is a lab-made antibody that works by blocking programmed death-ligand 1 (PD-L1), a protein that cancer cells use to hide from your immune system. When PD\u2011L1 is blocked, your T cells (a type of immune cell) can more easily see and attack cancer cells. But because PD-L1 is also on normal cells, Tecentriq can affect those cells as well. Tecentriq is given intravenously (as an IV), whereas another form of the same medicine, Tecentriq Hybreza, is given as an under\u2011the\u2011skin shot, also called a subcutaneous (SC) injection.<\/p>\n

This approval matters because it reduces the concern that patients and families face after bladder removal surgery. It is the first FDA approval to use ctDNA results to guide therapy. It offers a more focused way to assess the risk of cancer recurrence, based on a blood\u2011based signal rather than imaging alone. Patients are selected for treatment based on serial ctDNA testing, which can begin at least six weeks after surgery and continue for up to a year. This approach helps target patients at a higher risk of recurrence while safely sparing lower-risk patients from unnecessary treatment and its side effects.<\/p>\n<\/section>\n

\n

Why Was It Approved?<\/h2>\n

The FDA’s approval was based on data from a clinical study that showed that Tecentriq lowered the risk of disease recurrence or death and prolonged disease-free survival (DFS), compared with a placebo, in adults with MIBC who had their bladder and nearby lymph nodes removed and were positive for MRD on serial ctDNA blood tests.<\/p>\n<\/section>\n<\/div>\n

\n
The clinical study involved 250 patients who did not show evidence of MIBC and were positive for MRD during serial ctDNA testing of blood, starting at least six weeks after the surgery (cystectomy) and continued for up to a year. No cancer was seen on imaging at the start of therapy. Patients were randomly selected to receive either Tecentriq or a placebo given by IV every four weeks for up to 12 cycles or one year.<\/p>\n

The main measure of benefit was how long people lived without the cancer coming back (DFS), and overall survival (OS) that showed how long they lived in total. The median DFS was 9.9 months with Tecentriq versus 4.8 months with a placebo, whereas the median OS was 32.8 months with Tecentriq versus 21.1 months with a placebo. The hazard ratio was 0.64 for DFS and 0.59 for OS, meaning the treatment reduced the risk of disease recurrence by 36% and the risk of death by 41%, respectively, compared with a placebo.<\/p>\n<\/section>\n

Side effects were in line with what is already known for Tecentriq. Common side effects when it is used alone include tiredness, low appetite, nausea, coughing, and shortness of breath. Tecentriq can also cause your immune system to attack normal organs such as the lungs, liver, intestines, hormonal glands, kidneys, skin, and other parts of the body, which may lead to serious or life\u2011threatening complications. Your health care provider may pause treatment and prescribe steroids or other therapies if needed.<\/p>\n

Other warnings include serious infusion reactions, rejection of a transplanted organ or tissue, and complications after a stem cell transplant that uses donor stem cells (allogeneic).<\/p>\n<\/section>\n

\n

What Do I Need to Know?<\/h2>\n

Tecentriq is given as an IV over 30 to 60 minutes. It is usually given every two, three, or four weeks for up to a year, unless the cancer returns or side effects are not tolerable. Tecentriq Hybreza is given as an under-the-skin shot every three weeks for up to a year, and the same stopping rules as Tecentriq apply. Your health care provider will choose the dosing schedule that fits your treatment plan. If you miss a dose, call your health care provider right away and reschedule it.<\/p>\n<\/section>\n<\/div>\n

\n
Let your health care provider know if you have problems with your immune system such as Crohn’s disease, ulcerative colitis, or lupus; have received radiation treatment to your chest; and have nervous system issues such as myasthenia gravis or Guillain-Barr\u00e9 syndrome. Be sure to tell your health care provider about all medicines you take, including prescription and over-the-counter drugs, vitamins, and herbal supplements.<\/p>\n

Be sure to let your health care provider know if you have received an organ or tissue transplant (including a corneal transplant) or an allogenic stem cell transplant, as Tecentriq may raise the risk of transplant rejection and has been linked to serious problems after an allogeneic transplant.<\/p>\n

Tell your health care provider if you are pregnant or planning to become pregnant, as Tecentriq may harm a fetus. Your provider will do a pregnancy test before treatment, and you should use effective birth control during treatment and for five months after your last dose. Avoid breastfeeding during treatment and for five months after your last dose, as it is not known whether Tecentriq passes into breast milk.<\/p>\n

Tecentriq and Tecentriq Hybreza activate your immune system to fight cancer, but they can also cause your immune system to attack normal organs and tissues. Call your health care provider right away if you notice a new cough; shortness of breath; belly pain; yellowing of the skin or eyes; dark urine or decreased urine output; severe diarrhea; black, tarry, sticky stools or stools with blood or mucus; a severe rash or itching; eye pain or blurry vision; weight gain or loss; changes in mood or behavior; confusion; sleepiness; memory problems; hair loss; swollen ankles; rapid irregular heartbeats; or severe muscle pain or weakness. These could be signs of serious side effects. Infusion reactions can also happen and may be severe.<\/p>\n<\/section>\n<\/div>\n<\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Tecentriq (atezolizumab) and\u00a0Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) are prescription immunotherapy medicines used to help the body’s immune system fight cancer. The FDA has now approved them to treat muscle-invasive bladder cancer (MIBC) in adults after surgery (cystectomy) when circulating tumor… <\/p>\n","protected":false},"author":2,"featured_media":336,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[],"class_list":["post-334","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-healthy"],"_links":{"self":[{"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/posts\/334","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/comments?post=334"}],"version-history":[{"count":1,"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/posts\/334\/revisions"}],"predecessor-version":[{"id":337,"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/posts\/334\/revisions\/337"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/media\/336"}],"wp:attachment":[{"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/media?parent=334"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/categories?post=334"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/noimfine.com\/sph06\/wp-json\/wp\/v2\/tags?post=334"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}